コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 est in harnessing these receptors to augment tumor immunity.
2 iltrating T cells results in diminished anti-tumor immunity.
3 the mechanism by which OX40 may impact anti-tumor immunity.
4 Rs and play important roles in microbial and tumor immunity.
5 tion, tumor angiogenesis, and suppression of tumor immunity.
6 to reverse this phenomenon and promote anti-tumor immunity.
7 s prevented T-cell tolerization and restored tumor immunity.
8 responses, as well as their contribution to tumor immunity.
9 deregulate the immune response and favor pro-tumor immunity.
10 ing involvement of SOCS3 in autoimmunity and tumor immunity.
11 membrane target antigens using humoral anti-tumor immunity.
12 to the tumor microenvironment restrains anti-tumor immunity.
13 indicates that B cells are involved in anti-tumor immunity.
14 vaccine adjuvants for infectious disease and tumor immunity.
15 ating Th cell development, inflammation, and tumor immunity.
16 RCA function to disable T cell-mediated anti-tumor immunity.
17 g the generation of innate and adaptive anti-tumor immunity.
18 regulating the balance between pro- and anti-tumor immunity.
19 e bottleneck, which precludes efficient anti-tumor immunity.
20 pid vessel loss, which does not support anti-tumor immunity.
21 latory T cells (Tregs) are a barrier to anti-tumor immunity.
22 ophages (TAMs) may have an important role in tumor immunity.
23 t therapeutic B cell depletion would enhance tumor immunity.
24 asthma, and allergic responses as well as in tumor immunity.
25 of immunosuppression hinder productive anti-tumor immunity.
26 in restraining PD1 expression and promoting tumor immunity.
27 t NK-DC interactions without compromising NK tumor immunity.
28 l memory phenotype associated with long-term tumor immunity.
29 cular pathway to inhibit CD8 T-cell-mediated tumor immunity.
30 and Th17 cells may play a protective role in tumor immunity.
31 in D signaling in humans could suppress anti-tumor immunity.
32 partial loss of TcR-I effector functions and tumor immunity.
33 ent to tumors and in regulation of effective tumor immunity.
34 ole for this receptor in HSP70.PC-F-mediated tumor immunity.
35 1alpha/VEGF-A axis is an essential aspect of tumor immunity.
36 se findings suggests a new interpretation of tumor immunity.
37 rstood type II NKT cell in the regulation of tumor immunity.
38 plicates in cancer cells while inducing anti-tumor immunity.
39 ory Siglecs that can potentially dampen anti-tumor immunity.
40 through the production of MDSC which inhibit tumor immunity.
41 rs in the tumor microenvironment that defeat tumor immunity.
42 hich serves a critical role in microbial and tumor immunity.
43 that Id is not a major target of the induced tumor immunity.
44 tumor growth, metastasis, and modulation of tumor immunity.
45 ntigens that can potentially elicit specific tumor immunity.
46 affinity T cells is insufficient to mediate tumor immunity.
47 nsplant rejection and toward modification of tumor immunity.
48 chronic infection and, perhaps, for improved tumor immunity.
49 heir potential relevance to autoimmunity and tumor immunity.
50 and tolerance to self and induce protective tumor immunity.
51 enuation as well as the facilitation of anti-tumor immunity.
52 subset distribution and function to subvert tumor immunity.
53 d their function, which might be critical in tumor immunity.
54 cells into tumor-bearing mice enhanced anti-tumor immunity.
55 rtoire can be exploited for the induction of tumor immunity.
56 cells and augments antigen-specific CTL anti-tumor immunity.
57 DCs strongly enhances antigen-specific anti-tumor immunity.
58 s and their ability to induce efficient anti-tumor immunity.
59 T cells (iNKTs) are potentially important in tumor immunity.
60 ironment, promote DC activation, and enhance tumor immunity.
61 grammed into indispensable mediators of anti-tumor immunity.
62 complete tumor regression along with lasting tumor immunity.
63 gen 4 (CTLA-4) further limits the potency of tumor immunity.
64 a potential role of B7-H4 in the evasion of tumor immunity.
65 0(25-33) minigene did not develop protective tumor immunity.
66 es, which together are required for effector tumor immunity.
67 erefore IL-13 deficient also have heightened tumor immunity.
68 cytokines with the capacity to augment anti-tumor immunity.
69 ical role in both afferent and efferent anti-tumor immunity.
70 vo, namely delayed-type hypersensitivity and tumor immunity.
71 ation of immune tolerance, autoimmunity, and tumor immunity.
72 ance of the immune response in favor of anti-tumor immunity.
73 a signaling leads to the enhancement of anti-tumor immunity.
74 icity and its role in the activation of anti-tumor immunity.
75 the tumor microenvironment while empowering tumor immunity.
76 xis mediates suppression of T-cell-dependent tumor immunity.
77 isease and graft rejection and promotes anti-tumor immunity.
78 riasis, but pDCs are also involved in (anti-)tumor immunity.
79 ve review of Eph receptors in the context of tumor immunity.
80 on ligands and thereby negated adaptive anti-tumor immunity.
81 f tumor antigens and thereby stimulates anti-tumor immunity.
82 play complex and poorly understood roles in tumor immunity.
83 ole of the Hippo pathway in suppressing anti-tumor immunity.
84 vating TLR4 agonist capable of inducing anti-tumor immunity.
85 ing, and impairment of T cell-dependent anti-tumor immunity.
86 o reveal a role for zinc homeostasis in anti-tumor immunity.
87 cells pose a major barrier to effective anti-tumor immunity.
88 alphabeta T cell receptor (TCR) mediate anti-tumor immunity.
89 paradoxical and poorly understood effects on tumor immunity.
90 ic niche formation and the induction of anti-tumor immunity.
91 o be a major contributor to compromised anti-tumor immunity.
92 ting T cell function, autoimmunity, and anti-tumor immunity.
93 immune responses that are required for anti-tumor immunity.
94 T cell function during autoimmunity and anti-tumor immunity.
95 tant tools to investigate carcinogenesis and tumor immunity.
96 requirements to elicit and maintain durable tumor immunity.
97 ory apoptosis reduced priming efficiency and tumor immunity.
98 ing ongoing (rather than generating de novo) tumor immunity.
99 se availability to T cells, suppressing anti-tumor immunity.
100 s Treg instability locally and restores anti-tumor immunity.
101 entral roles in infection, autoimmunity, and tumor immunity.
102 mor-infiltrating dendritic cells blunts anti-tumor immunity.
103 n cancer (OvCa) progression by blunting anti-tumor immunity.
104 ant melanoma, by impeding IgG1-mediated anti-tumor immunity.
105 hophysiological context: suppression of anti-tumor immunity.
106 cancer cells, as well as in suppressing anti-tumor immunity.
107 issues function in parallel to restrict anti-tumor immunity.
108 rovide therapeutic benefit by enhancing anti-tumor immunity.
109 of autoimmunity and the suppression of anti-tumor immunity.
110 umor microenvironment that can suppress anti-tumor immunity.
111 FOXP3-specific T cell responses and enhances tumor immunity.
115 erful system for evaluating antigen-specific tumor immunity against spontaneous tumors arising in an
116 ells are the major regulators of concomitant tumor immunity against this weakly immunogenic tumor.
117 ar immunity and failed cytotoxic T cell anti-tumor immunity, alter cancer risk and therefore represen
118 s are important and potent mediators of anti-tumor immunity and adoptive transfer of specific CD4(+)
121 In this study, we tested the balance between tumor immunity and autoimmunity in neu-transgenic BALB N
122 en-specific cells increased vaccine-elicited tumor immunity and autoimmunity, but a threshold was rea
126 appreciated roles for IL-35 in limiting anti-tumor immunity and contributing to T cell dysfunction in
127 suppressive mechanisms used by MDSC to block tumor immunity and describes the mechanisms by which inf
128 data show that the anti-OX40-enhancement of tumor immunity and effector T cell numbers is decreased
129 ng pathways, can contribute to decrease anti-tumor immunity and enhance cell proliferation and oncoge
131 ypothesized that integrin beta3 could affect tumor immunity and evaluated tumors in mice with deletio
132 sms and tumors to attenuate antimicrobial or tumor immunity and facilitate chronic infection and tumo
133 ro-inflammatory environment may curtail anti-tumor immunity and favor cancer initiation and progressi
134 ary-administered DC-AdCCL21 in regulation of tumor immunity and genetic immunotherapy for lung cancer
135 onale for further evaluation of ELC/CCL19 in tumor immunity and its use in cancer immunotherapy.
136 dditional evaluation of SLC in regulation of tumor immunity and its use in lung cancer immunotherapy.
137 onstrate a novel pathway for B7DC to promote tumor immunity and may reconcile the apparently contradi
138 thers in early development, can unleash anti-tumor immunity and mediate durable cancer regressions.
139 These results suggest a role for IL-9 in tumor immunity and offer insight into potential therapeu
140 oregulatory axis with broad implications for tumor immunity and other immunological and disease setti
141 ss the local and systemic effects of VEGF on tumor immunity and propose a potentially translatable st
142 ex-dependent, B7-H1-dependent differences in tumor immunity and response to immunotherapy in a hormon
143 intracellular checkpoint in NK cell-mediated tumor immunity and suggest possibilities for new cancer
144 h other check-point inhibitors enhances anti-tumor immunity and suppresses tumor growth in several pr
145 ed to play a critical role in the evasion of tumor immunity and the amelioration of allogeneic transp
148 -origin cells that are potent suppressors of tumor immunity and therefore a significant impediment to
149 d that Cu- and Zn-AMSs markedly induced anti-tumor-immunity and enhanced CD4(+) and CD8(+) T cell pop
152 on in regulating autoimmunity and tolerance, tumor immunity, and host defense against intracellular p
154 involved in regulation of immune tolerance, tumor immunity, and immunity to infectious pathogens.
155 r role in tumor-associated blood vessels and tumor immunity, and provide an update on mTOR inhibitors
156 hanistic insights into the role of TR-CD4 in tumor immunity, and suggest that approaches to utilize T
157 ived Ags leading to long-lived systemic anti-tumor immunity, and suggests a paradigm for clinical int
160 ect susceptibility to infection or graft-vs.-tumor immunity are hampered by the lack of a physiologic
161 production of antibodies to SV40 Tag and in tumor immunity as the result of recombinant SV40 Tag imm
163 of effector immune responses is pivotal for tumor immunity as well as for successful anticancer vacc
164 utes to the protection against the host anti-tumor immunity as well as to the survival of invading an
166 utoimmune skin depigmentation (vitiligo) and tumor immunity, because they are expressed by both benig
167 ical role not only in the down-regulation of tumor immunity but also in the promotion of the immunity
168 ry NKG2D receptor on T and NK cells mediates tumor immunity but can also promote local and systemic i
170 regs is necessary to abrogate suppression of tumor immunity, but a third cell, the type I NKT cell, d
171 re innate immune cells that are important in tumor immunity, but also have the ability to modulate th
172 umor-specific rejection antigens for natural tumor immunity, but we know remarkably little about T-ce
173 ffector cell immunotherapy mediate long-term tumor immunity by different mechanisms that subsequently
174 ttern on malignant cells potentially affects tumor immunity by directly influencing interactions with
176 etween MDSC and macrophages further subverts tumor immunity by increasing MDSC production of IL-10, a
178 D-1/PD-L1 blockade enhanced the amplitude of tumor immunity by reprogramming suppressive and stimulat
181 ptide ligands in order to induce strong anti-tumor immunity capable of breaking tolerance toward thes
182 ulation of the immune system to amplify anti-tumor immunity carries the risk of developing autoimmune
183 ed by a native tumor-antigen boost, improves tumor immunity compared with T cells elicited by the sam
184 data suggest the importance of Th17 cells to tumor immunity, conclusions regarding the functional rol
187 e have therefore demonstrated that effective tumor immunity correlates with the presence of endogenou
188 restoration of TTP expression enhances anti-tumor immunity dependent on degradation of PD-L1 mRNA.
190 cted NKT cells play a role in suppression of tumor immunity, depletion of CD4+CD25+ T cells did not i
194 to the general mechanisms of vaccine-induced tumor immunity directed toward tumors bearing distinct t
195 al killer (NK) cells are critical for innate tumor immunity due to their specialized ability to recog
196 In additional studies in vivo, protective tumor immunity elicited by tumor-derived gp96-peptide co
198 ) as the most potent molecule for augmenting tumor immunity following gene transfer into melanoma cel
199 ure immune system, we detect measurable anti-tumor immunity from very early stages, which is driven b
201 cape of a tumor shapes and is shaped by anti-tumor immunity has not been systematically explored.
206 cells may not have direct effector roles in tumor immunity, impaired T cell activation, and enhanced
207 ring mice and stresses the value of studying tumor immunity in a therapeutic rather than a prophylact
209 0 Tag protein immunization mounted effective tumor immunity in an established experimental pulmonary
210 ontrol of TH9 differentiation regulated anti-tumor immunity in an experimental melanoma-bearing model
211 nt study, we investigated the development of tumor immunity in an HLA-A0201(+) MM patient who achieve
212 ers T cell glycolytic metabolism and affects tumor immunity in cancer patients remains a question.
216 poietic 5-lipoxygenase (5LO) that may impact tumor immunity in development of colon cancer has not be
217 etion of CD8(+) T lymphocytes did not impair tumor immunity in either immune phase and resulted in th
219 have demonstrated augmented T cell-mediated tumor immunity in genetically B cell-deficient mice, sug
225 TLA-4) blockade, an approach that can induce tumor immunity in other tumor models, did not result in
227 gest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer pati
229 ion was not as effective in the induction of tumor immunity in therapeutic modalities when compared w
231 1d-restricted NKT cells in the regulation of tumor immunity, in that type II NKT cells may be suffici
232 filtrating myeloid cells (TIM) that suppress tumor immunity, including M2 macrophages and myeloid-der
233 ion of CD8, but not CD4 T cells reduced anti-tumor immunity, indicating CTL as the effector cells.
234 evaluate the role of T lymphocyte subsets in tumor immunity induced by recombinant SV40 large tumor a
235 the immune components necessary for systemic tumor immunity induced upon immunization with plasmid DN
236 owever, the role of B7 molecules in inducing tumor immunity is controversial because of conflicting r
238 tion of suppressor cells which down-regulate tumor immunity is one of the mechanisms linking inflamma
246 nce of CD4 T cells, development of long-term tumor immunity (memory) was severely compromised as refl
247 c cells (DCs) have long been known to affect tumor immunity, our data also implicate DCs in regulatio
248 s immunomodulatory activities to induce anti-tumor immunity predict the suppression of tumor growth.
257 CLTA-4(-/-) T-cell-mediated autoimmunity and tumor immunity required CD4(+) T cells in which the func
261 nant spreading and the induction of systemic tumor immunity resulting in indigenous tumor rejection.
265 e cytotoxic effector response away from anti-tumor immunity ('sword') and towards proinflammatory and
266 challenge resulted in greater attenuation of tumor immunity than observed with selective depletion of
269 d DNA induce autoimmune hypopigmentation and tumor immunity through cross-recognition of nonmutated g
270 h17 cells may contribute to protective human tumor immunity through inducing Th1-type chemokines and
271 madelta T cells can play a necessary role in tumor immunity through provision of an early source of I
273 t instead impede development of desired anti-tumor immunity, thus providing synergistic effects betwe
275 for tumor-derived HSP70 in facilitating anti-tumor immunity to limit tumor growth and highlight the p
277 he regulation of processes ranging from anti-tumor immunity to the adjuvant action of aluminum hydrox
278 m and split tolerance, with implications for tumor immunity, transplantation, autoimmunity, and repro
280 inguish the genetic and immune regulation of tumor immunity versus autoimmunity, immune responses to
285 ell regulation in the control of spontaneous tumor immunity, we analyzed NY-ESO-1-specific Th1 cell i
286 of tumor-derived IL-35 in tumorigenesis and tumor immunity, we generated IL-35-producing plasmacytom
287 y a vital role in developing and maintaining tumor immunity, we investigated the presence of a CD4(+)
289 To investigate the role of IL-13Ralpha2 in tumor immunity, we used D5 melanoma cells stably transfe
290 , complete tumor regression and long-lasting tumor immunity were observed, still without adverse effe
291 NA expression for genes associated with anti-tumor immunity were obtained from the invasive breast ca
292 4(+) T cells and may therefore contribute to tumor immunity, whereas a peptide overlapping the juncti
295 d CD4(+) T cells, promotes and enhances anti-tumor immunity with limited success on large tumors in m
297 immune cell components that lead to systemic tumor immunity within an experimental pulmonary metastat
298 e results demonstrate that the mechanisms of tumor immunity within the brain are different from those
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。